INCY - Incyte says study evaluating efficacy of ruxolitinib cream in children met primary endpoint

2023-10-13 11:28:03 ET

Biopharmaceutical Incyte ( NASDAQ: INCY ) Friday announced that the phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream, Opzelura, in children between ages 2 - 12 with atopic dermatitis met its primary endpoint.

Data from the TRuE-AD3 study showed the study met its primary endpoint, with significantly more patients treated with ruxolitinib cream (0.75% and 1.5%) achieving Investigator’s Global Assessment Treatment Success than patients treated with non-medicated cream.

In addition, secondary endpoints such as time to NRS4 (?4-point improvement in itch Numerical Rating Scale [NRS] score) and patients demonstrating at least a 75% improvement in the Eczema Area and Severity Index at week 8 were also achieved.

Incyte added that in a second study, treatment with ruxolitinib cream over eight weeks under maximum-use conditions was well tolerated in children (age ?2 to <12 years).

Atopic dermatitis is the most common type of eczema, which is a chronic skin disease characterized by inflammation and itching.

More on Incyte

• FDA approves GSK drug Ojjaara for myelofibrosis with anemia (update)
• AbCellera, Incyte partner for antibody-based cancer drugs
• Seeking Alpha’s Quant Rating on Incyte

For further details see: